- Home
- SPRO vs DXR Comparison
SPRO vs DXR Comparison
Compare SPRO & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPRO | DXR |
|---|---|---|
| Founded | 2013 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.0M | 59.0M |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | SPRO | DXR |
|---|---|---|
| Price | $1.07 | $9.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $5.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 461.5K | 12.0K |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | $1,446,345.00 |
| Revenue This Year | N/A | $44,489.33 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $1.08 | $8.56 |
| 52 Week High | $3.08 | $14.76 |
Technical Indicators
Market Signals| Indicator | SPRO | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 27.62 |
| Support Level | N/A | $8.56 |
| Resistance Level | $1.28 | $12.07 |
| Average True Range (ATR) | 0.06 | 0.38 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 0.00 | 6.15 |
Price Performance
Historical ComparisonAbout SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.